vesleteplirsen

After serious side effect, Sarepta and FDA realign on next-gen Duchenne drug with trial hold lifted
Endpoints
Tue, 09/6/22 - 10:48 am
Sarepta Therapeutics
Duchenne Muscular Dystrophy
vesleteplirsen
clinical trials